admin

Lisbon, Portugal and Shanghai, China – Hovione, the leader in spray drying and particle engineering, announced today an exclusive license agreement for a preclinical ophthalmology program, JX08, with Ji Xing Pharmaceuticals Limited (JIXING).

JIXING is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW), a leading life sciences investment firm, that is focused on advancing innovative medicines for patients with ophthalmic and cardiovascular diseases. Under the license agreement, JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization. [Read more…] about Hovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

SEOUL, South Korea, Jan. 4, 2022 / PRNewswire – BIORCHESTRA and SK Biopharmaceuticals announced today that they have forged a partnership to research and develop new therapeutic compounds targeting microRNAs [1] (miRNA) for a potential treatment of epilepsy.

Under the collaboration agreement, BIORCHESTRA, a South Korea-based privately-held biotech company that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology.

BIORCHESTRA has a platform using antisense oligonucleotides[2] (ASO) to inhibit and regulate miRNA function, and a proprietary drug delivery system (BDDSTM) that penetrates the blood-brain barrier (BBB) and delivers RNA drugs to the brain.

SK Biopharmaceuticals, a global innovative pharmaceutical company, will validate disease-modifying targets, as well as carry out preclinical studies. [Read more…] about BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics